
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Saama Technologies, a clinical and health data analytics company, and ICON plc, a global provider of drug development and commercialization solutions and services, have partnered to accelerate the use of Real World Evidence across the product lifecycle and drive mission critical decisions for medical affairs, reimbursement, and commercialization functions.
Read the full release






